Production (Stage)
Caribou Biosciences, Inc.
CRBU
$1.12
$0.010.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.35M | 2.08M | 2.02M | 3.46M | 2.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.35M | 2.08M | 2.02M | 3.46M | 2.43M |
| Cost of Revenue | 1.74M | 29.86M | 29.82M | 35.48M | 1.62M |
| Gross Profit | 610.00K | -27.79M | -27.80M | -32.02M | 812.00K |
| SG&A Expenses | 9.74M | 10.49M | 5.94M | 11.49M | 14.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.27M | 40.35M | 35.76M | 46.97M | 48.43M |
| Operating Income | -42.91M | -38.28M | -33.74M | -43.50M | -46.00M |
| Income Before Tax | -39.99M | -35.50M | -34.68M | -37.70M | -41.23M |
| Income Tax Expenses | -- | -9.00K | -- | -- | -- |
| Earnings from Continuing Operations | -39.99M | -35.49M | -34.68M | -37.70M | -41.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.99M | -35.49M | -34.68M | -37.70M | -41.23M |
| EBIT | -42.91M | -38.28M | -33.74M | -43.50M | -46.00M |
| EBITDA | -41.75M | -37.09M | -32.56M | -42.65M | -45.29M |
| EPS Basic | -0.43 | -0.39 | -0.38 | -0.42 | -0.46 |
| Normalized Basic EPS | -0.27 | -0.24 | -0.21 | -0.26 | -0.29 |
| EPS Diluted | -0.43 | -0.39 | -0.38 | -0.42 | -0.46 |
| Normalized Diluted EPS | -0.27 | -0.24 | -0.21 | -0.26 | -0.29 |
| Average Basic Shares Outstanding | 92.68M | 91.16M | 90.46M | 90.34M | 89.30M |
| Average Diluted Shares Outstanding | 92.68M | 91.16M | 90.46M | 90.34M | 89.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |